This gene overview is brought to you as part of Tempus’ goal to inform providers about our genomic testing panels and the genes included in our offerings. Through our robust de-identified database of clinical information coupled with molecular testing results, we are capable of providing unique insights into these gene alterations. Many of the gene alterations reported on our somatic and germline panels are often key inclusion criteria for clinical trials.
The mTOR gene encodes a phosphatidylinositol serine/threonine kinase protein that functions in response to DNA damage and nutrient deprivation. It is part of the mTORC1 and mTORC2 signaling complexes that regulate translation, and its function in the PI3K-AKT-mTOR signaling pathway regulates cellular proliferation and survival. Activating mutations and overexpression of mTOR are associated with cancer progression.
mTOR alterations in 10 most common cancers—Tempus database
FDA approved mTOR inhibitors
|Therapy||Tumor type (indication)||Biomarker|
|TORISEL® temsirolimus||renal cell carcinoma||none|
|AFINITOR® everolimus||tuberous sclerosis complex (TSC)–associated renal angiomyolipoma||TSC|
|AFINITOR® everolimus||breast cancer||HR+/HER2-|
|AFINITOR® everolimus||neuroendocrine tumors||none|
|AFINITOR® everolimus||renal cell carcinoma||none|
Select strategies in clinical development targeting mTOR signaling
|multi-kinase inhibitor||samotolisib (LY3023414)|
|mTOR inhibitor||sapanisertib (TAK-228) nab-rapamycin (ABI-009) AZD2014 MLN0128|
View a more comprehensive list of clinical trials for patients with mTOR mutated cancers. The Tempus TIME Trial® Program brings the right clinical trials to the right patients, in days instead of months. Learn how you can enroll today.